Portfolio Risk
Cash runway vs days to next catalyst — spot binary event risk at a glance
| Company | Catalyst | Type | Days | Runway | Impact | Confidence |
|---|---|---|---|---|---|---|
| AVR | TCT 2026 DurAVR clinical data presentation | Conference | 6d | 1mo | medium | confirmed |
| TLX | ProstACT Global Phase 2 Part 2 U.S. Enrollment Initiation | Commercial | 6d | CF+ | high | expected |
| RAD | RAD101 Phase 3 Pivotal Trial Initiation | Commercial | 6d | 4mo | high | expected |
| BDX | R&D tax offset receipt | Financing | 6d | 3mo | medium | expected |
| TLX | PHASE1 data readout — PSMA PET Response Guided SabR in High Risk Pca | Data Readout | 7d | CF+ | medium | speculative |
| ACW | XanaMIA Phase 3 topline final efficacy results | Data Readout | 36d | 3mo | high | expected |
| KZA | PHASE1 data readout — GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain | Data Readout | 37d | 0mo | medium | speculative |
| IMR | Trial data readout — VT Ablation in the iCMR | Data Readout | 37d | CF+ | medium | speculative |
| RMD | Trial data readout — Study of Min-Max APAP Recommender Tool | Data Readout | 37d | CF+ | medium | speculative |
| IIQ | EXO-OC ovarian cancer test LDT readiness | Commercial | 67d | 11mo | high | expected |
| IMM | AIPAC-003 Phase III breast cancer update | Data Readout | 67d | CF+ | high | speculative |
| AVH | PermeaDerm I clinical study data readout | Data Readout | 67d | CF+ | medium | expected |
| AVH | 2026 revenue guidance $80-85M | Commercial | 67d | CF+ | medium | expected |
| IMM | TACTI-003 HNSCC registrational path decision | Regulatory | 67d | CF+ | high | speculative |
| CUV | CUV105 Vitiligo Phase III topline results | Data Readout | 67d | CF+ | high | expected |
| CUV | EMA filing for adolescent EPP label expansion | Regulatory | 67d | CF+ | medium | expected |
| CUV | CUV107 Phase III vitiligo trial initiation | Other | 67d | CF+ | medium | expected |
| IPD | US reimbursement expansion — ongoing | Commercial | 67d | 9mo | high | confirmed |
| AVR | PARADIGM interim 6-month safety data | Data Readout | 67d | 1mo | medium | expected |
| OCC | CelGro US Revenue Milestone | Commercial | 67d | 8mo | high | expected |
| PAR | PURIFY Phase 3 MPS Trial Topline Readout | Data Readout | 67d | 3mo | high | expected |
| ANP | ATL1102 Phase 2 DMD Readout (Percheron) | Data Readout | 67d | 0mo | high | expected |
| PIQ | Oxford University PromarkerEndo cohort (~600 samples) results | Data Readout | 67d | 5mo | medium | expected |
| SNT | AZALOX Phase 1b preliminary data readout | Data Readout | 67d | 25mo | high | expected |
| PYC | PYC-003 Phase 1a Data Readout | Data Readout | 67d | 26mo | high | expected |
| CUV | Nasdaq ADR upgrade to ADS listing | Commercial | 67d | CF+ | medium | expected |
| ILA | Galidesivir compassionate use treatment data generation in Uganda Ebola outbreak | Data Readout | 67d | 32mo | high | expected |
| SHL | LADR synergy realisation — first full year | Commercial | 67d | CF+ | medium | expected |
| MYX | US HRT black box warning removal — BIJUVA/IMVEXXY impact | Regulatory | 67d | CF+ | high | expected |
| RCE | RECCE 327 Phase 3 DFI full enrollment (310 patients) | Data Readout | 67d | 4mo | high | expected |
| RCE | Indonesia BPOM conditional approval | Regulatory | 67d | 4mo | high | speculative |
| ILA | ISLA-101 strategic partnership / licensing deal | partnership | 67d | 32mo | high | speculative |
| SOM | Rest Assure efficacy monitoring FDA 510(k) submission | Regulatory | 67d | CF+ | high | expected |
| IXC | Presendin IP/asset divestment or licensing deal | partnership | 67d | 24mo | high | speculative |
| ACR | Acyclovir Cream 5% FDA decision | Regulatory | 67d | 2mo | medium | expected |
| RAD | RAD202 Phase 1 HEAT Trial Dose Escalation Completion | Data Readout | 67d | 4mo | high | expected |
| UBI | Tn Antigen cancer biomarker feasibility data | Data Readout | 67d | 0mo | high | speculative |
| 1AD | AD-214 Phase 2 partner announcement / licensing deal | Commercial | 67d | 1mo | high | speculative |
| PAB | RLS-2201 Phase 0 clinical trial initiation | Regulatory | 67d | 13mo | high | expected |
| OSL | OncoSil Commercial Production Commencement | Commercial | 67d | CF+ | high | expected |
| ATH | ATH434 partnering/licensing deal | Financing | 67d | CF+ | high | speculative |
| HLS | Agilex Biolabs strategic review and potential sale completion | Commercial | 67d | 0mo | high | expected |
| AVR | CMS coverage determination decision | Regulatory | 67d | 1mo | high | expected |
| HLS | Fair Work Commission gender undervaluation impact on pathology labour costs | Regulatory | 67d | 0mo | medium | confirmed |
| ATX | Narmafotinib Phase 2b trial enrollment initiation | Commercial | 67d | 24mo | medium | expected |
| NSB | StemSmart Phase 2 Crohns disease trial initiation | Data Readout | 67d | 42mo | high | expected |
| PME | Implementation activity across H2 FY26 and into FY27 | Commercial | 67d | CF+ | high | expected |
| IIQ | Dual-action CAR-exosome data in TNBC cells | Data Readout | 67d | 11mo | high | expected |
| NEU | DAYBU European Commission Marketing Authorisation Decision | Regulatory | 67d | CF+ | high | expected |
| FPH | Trial data readout — myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home | Data Readout | 68d | CF+ | medium | speculative |
| CYC | International lung imaging clinical guidelines publication | Regulatory | 68d | CF+ | high | expected |
| CYC | 250-300 US Technegas installations target achievement | Commercial | 68d | CF+ | high | expected |